No Data
Guangdong Hybribio Biotech (300639.SZ): Plans to spend 0.05 billion yuan to -0.1 billion yuan to buy back shares.
Gelonghui, November 14 – Guangdong Hybribio Biotech (300639.SZ) announced that the company plans to use its own funds and bank special repurchase loan funds to repurchase a portion of its shares through a centralized bidding trading method (hereinafter referred to as "this repurchase plan"). The repurchased shares will be used to maintain the company's value and the rights of shareholders. The total amount of funds for repurchasing shares and the source of funds will be no less than 50 million RMB (inclusive) and no more than 100 million RMB (inclusive) from its own funds and bank special repurchase loan funds. The price for repurchased shares will not exceed 9.00 RMB/share (inclusive). The implementation period for the repurchased shares starts from
Guangdong Hybribio Biotech (300639.SZ): The company currently has no test reagents related to dengue virus.
On November 14, Gelonghui reported that guangdong hybribio biotech (300639.SZ) stated on the investor interaction platform that the company currently has no test reagents related to the dengue virus, but its medical laboratory has the capability to perform laboratory tests for the dengue virus.
Individual Investors Are Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥378m Last Week
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted two invention patent authorizations.
Galonnell 31st October, guangdong hybribio biotech (300639.SZ) announced that the company and its subsidiaries obtained 2 invention patents in October 2024, including a method for separating placental nourishing layer cells from pregnant women's cervical shedding cells, as well as a chloroquine gel and its preparation method and application.
Capbio: Report for the third quarter of 2024
Guangdong Hybribio Biotech (300639.SZ): The net loss in the first three quarters was 0.262 billion yuan.
On October 29, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ) released its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.61 billion yuan, a decrease of 28.26% year-on-year; the net income attributable to shareholders of the listed company was a loss of 0.262 billion yuan, a decrease of 252.19% year-on-year; the net income after deducting non-recurring gains and losses was a loss of 0.27 billion yuan, a decrease of 276.98% year-on-year; the basic earnings per share was -0.4068 yuan per share.
No Data
No Data